WORK Medical Technology Group Business Summary

WORK Medical Technology Group LTD (WOK) operates as a specialized manufacturer and global distributor of Class I and II medical consumables, generating revenue primarily through the direct sale of a 21-product portfolio to hospitals, pharmacies, and medical institutions. The company’s business is bifurcated into its core medical consumables segment—encompassing anesthesia masks, breathing circuits, and laryngeal tubes—and an emerging innovative equipment division focused on AI-automated diagnostic tools, such as its recently launched blood cell morphology analyzer. While the firm maintains a presence in over 30 countries, it derives the vast majority of its revenue from the Chinese domestic market. Within the competitive landscape, WOK competes against small-cap medical device firms like Dynatronics (DYNT), T2 Biosystems (TTOO), and Meihua International Medical Technologies (MHUA), positioning itself as a high-volume supplier currently undergoing aggressive capital restructuring to stabilize its Nasdaq listing and pivot toward higher-margin AI-integrated medical technology. The leadership team is spearheaded by Chairman and CEO Shuang Wu, who brings significant operational and financial pedigree from his previous tenure as COO of EZGO Technologies Ltd. Supporting the executive suite are CFO Ningfang Liang and COO Baiming Yu, the latter of whom oversees the company’s extensive manufacturing footprint in Hangzhou. The board of directors, which is currently undergoing a strategic refresh as of February 2026, includes independent members such as Robert Johnson, a CPA with extensive audit experience, Dr. Xiaoyang Li, and Zhenguo Wu. Notable institutional involvement includes previous backing from Univest Securities and Kingswood, alongside a recent strategic equity investment in Neologics Bioscience, reflecting a management mandate to diversify the company’s asset base beyond traditional disposables into advanced biotechnological research.